Tosato M, Varone F, Ciccullo A, Calvani R, Moschese D, Potenza A, Siciliano M, Fantoni M
Matteo Tosato, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, email:
J Frailty Aging. 2021;10(1):70-71. doi: 10.14283/jfa.2020.41.
COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, showed higher severity and lethality in male older adults . There are currently no specific treatments. Studies are evaluating the efficacy of monoclonal antibodies against interleukin-6 receptor. Here we present the case of a 98-years old man admitted to our COVID-Hospital with acute respiratory failure. Comprehensive geriatric assessment showed no signs of frailty. First-line therapy with hydroxychloroquine and anticoagulants was not effective. Patient was administered intravenous monoclonal antibodies, and he showed remarkable clinical improvement. This case suggests that age alone should not preclude access to new therapeutic approaches. Comprehensive, multisciplinary, multidomain approaches are needed to develop patient-tailored treatments against COVID-19.
新型冠状病毒肺炎（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起的疾病，在老年男性中表现出更高的严重程度和致死率。目前尚无特效治疗方法。多项研究正在评估抗白细胞介素-6受体单克隆抗体的疗效。在此，我们报告一例98岁男性因急性呼吸衰竭入住我院COVID-19病房的病例。综合老年评估显示无虚弱迹象。羟氯喹和抗凝剂的一线治疗无效。给予患者静脉注射单克隆抗体后，其临床症状显著改善。该病例表明，不应仅因年龄因素而拒绝给予新的治疗方法。需要综合、多学科、多领域的方法来制定针对COVID-19的个性化治疗方案。
